CSPC Pharmaceutical Group (HKG:1093) has agreed to grant an exclusive license to AstraZeneca to develop, manufacture, and commercialize its lipoprotein inhibitor YS2302018, and products that comprise or contain the compound, a Monday bourse filing said.
The firm will receive an upfront payment of $100 million under the license contract and be eligible for up to $370 million and $1.55 billion in potential development and sales milestone payments, respectively.
The pharmaceutical company will also receive tiered royalties based on annual net sales of the relevant products.
Shares of the company closed nearly 5% higher on Monday.
Price (HKD): $7.12, Change: $+0.31, Percent Change: +4.55%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。